Catalyst Dossier · compiled by CeliA 🧫

United Therapeutics Corporation (UTHR)

Pharmaceutical Preparations · market cap $22.8B · as of 2026-06-25

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-29

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

United Therapeutics Corporation (UTHR) is a ~$23B market cap specialty biotech focused on pulmonary diseases and organ manufacturing/xenotransplantation, generating $3.18B in 2025 revenue with $1.34B net income. The company runs a broad pipeline across multiple Phase 3 programs in pulmonary hypertension and pulmonary fibrosis, while pursuing a longer-dated xenotransplantation platform. Near-term catalysts are limited to a July 2026 earnings print, with a higher-impact Phase 2 MASH readout (UBT251) estimated for mid-2027.

The catalyst path

2026-07-29Earningsimp 5/10
2027-06-26 (est.)PDUFA · NCX 470imp 8/10

Pipeline

Asset	Phase	Indication
Inhaled Treprostinil	Phase 3	Progressive Pulmonary Fibrosis
UB-421(25 mg/kg) Q2W	Phase 2	HIV-1 Infection
Treprostinil Diolamine	Phase 3	Pulmonary Arterial Hypertension
Ralinepag	Phase 3	Pulmonary Arterial Hypertension
GGTA1 KO Thymokidney	Phase 2	ESRD (End-Stage Renal Disease)
APD811	Phase 2	Pulmonary Arterial Hypertension
UT-15	Phase 3	Pulmonary Hypertension
oral treprostinil	Phase 3	PAH
UT-15C SR	Phase 3	Pulmonary Hypertension
ch14.18 -NCI	Phase 2	Neuroblastoma
UT-15C (treprostinil diolamine)	Phase 3	Pulmonary Arterial Hypertension
Dinutuximab	Phase 3	Small Cell Lung Cancer
10 GE Xenokidney	Phase 2	ESRD (End-Stage Renal Disease)
Oral treprostinil (UT-15C) Sustained Release Tablets	Phase 3	Pulmonary Hypertension
treprostinil diethanolamine	Phase 3	Pulmonary Arterial Hypertension
UT-15C	Phase 2	Pulmonary Hypertension
Tyvaso Inhalation Solution	Phase 2	Pulmonary Arterial Hypertension
UB-421	Phase 2	HIV-1 Infection
0.5% Ivermectin lotion	Phase 2	Pediculosis Capitis

Price & technical context

3-month

-2.5%

6-month

+12.0%

12-month

+88.8%

52-wk range

$274.70–$596.76

vs 50-day MA

-0.7%

vs 200-day MA

+10.2%

Realized vol

48.2%

Max drawdown

-33.0%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for UTHR (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 19 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.